Should you buy Pfizer shares on the stock market in 2026?

Rising since the start of the coronavirus, the Pfizer action, current leader in the health and pharmaceutical sector on the American stock exchange, would surely be one of the most interesting investments on the market. Find out in this article how Buy Pfizer stock under the best conditions and analyze its price.

Should you buy the stock on the stock market?

<

Also remember to choose a broker who has thevantage to offer a complete offer for buy stocks of the whole world ! This will allow you to diversify your portfolio later.

Stock Price () in Real Time

Right now, you can buy the stock at the price of per share. Since the start of the day, the price of has changed by %.

This morning at the opening the share price was . During the session, the highest the stock price reached was while the lowest was and today's closing price was .

Over one year (the past 52 weeks) the share price reached a high of , and the lowest reached over the last 52 weeks was .

Should You Buy Stocks in 2026?

Currently the share price is and pays a dividend of per share! The dividend yield rate is % per year if you buy the shares at the current price.

Should You Buy Pfizer Stock?

The progression of the title on the market is very favorable to the opening of positions at this time. Pfizer having been the first to offer vaccines against Covid 19, it remains a very good long-term investment.

• The stock price has been trending upward since May 2020, particularly after the announcement of the Covid-19 vaccine. This price movement makes buying the stock a favorable opportunity. In fact, its price has risen by more than 0,8% in recent weeks, which represents a considerable gain if you invested, for example, six months ago.
• A very long-term vision. With the spread of Covid-19, the Pfizer vaccine has gained ground since its announcement and is being used more and more effectively.

Pfizer Action Opinion – Pfizer has a future as an investment?

The pharmaceutical sector has become increasingly promising since the start of the coronavirus pandemic in France, Europe, and worldwide. Human lives are currently somewhat dependent on COVID-19 treatments. The Pfizer vaccine is therefore in high demand due to its effectiveness in protecting against the virus.

In addition to that, It also pays a dividend to stand out in this highly competitive industry in order to secure shareholder investment.

With its market capitalization of $327,79 billion, Pfizer shows thatIt is one of the most promising stocks on the stock market right now. Furthermore, it is currently one of the giants of the pharmaceutical sector.

Pfizer Share Dividends – History of Dividends Distributed

Yield Buy Pfizer – What Yield on the Action?

Buy Pfizer Stock or Sell Pfizer Stock in 2026?

Analyst analysis currently shows that Pfizer stock should be bought. The analysis is based on the following points:

• Earnings per share increase: Looking at the analysis, we can see that earnings per share will continue to increase in 2026, making the investment more attractive.
• Increase in revenue: In addition to the increase in earnings per share, Pfizer's group revenue is also expected to continue to increase in 2026.
• A cheap stock: The stock price is not yet very expensive, as it currently costs less than 60 euros.

We therefore recommend that you add Pfizer stock to your portfolio in 2026.

With which stock exchange products should I buy Pfizer shares?

To invest and profit from stock prices, you need to choose an ideal product to invest in.

• Buy Pfizer shares for cash with DEGIRO.
• Get an ETF with Pfizer shares – always with DEGIRO.
• Buy Pfizer shares with leverage – with the broker Vantage.
• Buy through the Pfizer Index with Vantage.
• Trade Pfizer stock with CFDs – with Vantage.

Pfizer Stock Price Prediction

The above forecasts do not constitute a certainty but are the result of estimates made by analysts.

Pfizer Price Analysis

Should You Buy This Month? – Pfizer Equity Fundamental Analysis

• Good ESG score from Refinitiv – Pfizer's score is quite good compared to its industry. For your information, this score is based on a company's ranking within its sector.
• EBITDA on the rise – Pfizer Group’s EBITDA or Earnings Per Share is on the rise and is expected to continue in this direction in the long term.
• A significant dividend – Pfizer remains an attractive yield stock with relatively large expected dividends.
• Analyses that differ – Finally, analysts' conclusions sometimes differ greatly on this stock, which is still difficult to assess because the group is in the midst of a merger with other laboratories.

Should I Buy Right Away? – Pfizer Stock Technical Analysis

• The Pfizer stock chart trend line is somewhat profitable in the near term or tomorrow. Since the stock price is going up, it is better to open a position immediately before the price goes too high.
• The RSI is well above 50, which confirms the good direction of the title.
• Stochastic indicators show neutral buy and overbought signals.
• Moving averages send a strong buy signal.

In conclusion, the technical analysis of the Pfizer share returns a buy signal on this security in the short, medium and long term. The next resistances are located at 58.60 and 76.13 and the next supports are located at 45.95 and 25.53.

Why invest in Pfizer Stock?

• It distributes dividends. Companies that pay dividends are few in the stock market. The company ensures that its investors receive substantial dividends, which is proof of liquidity and stability.
• They distribute increasing dividends to their investors, regardless of the situation or the progress of the stock market.
• It is a stable company. Its market capitalization is very good, which places it at the top of the companies with the best capitalizations in terms of health in the world.
• They merge with many companies in its sector, which gives them incredible strength to move forward despite the crisis.

Buy Pfizer Stock or Bayer Stock

The Pfizer Company – Does It Have a Future?

For Shareholders:

The dividends paid by the group are generous. No matter how good the company's results are, as we have seen recently, it still pays dividends to its investors to keep them happy. Their dividends continue to grow even if the stock price falls. So it's one of thevantages to be a shareholder of this group.

For Investors:

Investors will not necessarily have the samevantages than the shareholders. They are benefiting from the stock's trend and right now it is very profitable for investors because it is trending up and is expected to do so.

For both:

The group's forecasts for the coming years are positive, with a return to profits and an increase in the dividend.

Market Cap & Key Figures Pfizer Share US7170811035

Buying Pfizer Stock – It's Investing in the Pharmaceutical Business

The pharmaceutical sector is undoubtedly one of the most profitable sectors in this period of the Covid 19 pandemic.

The figures prove that the pharmaceutical sector is experiencing an average growth of 6% each year, in addition to the health needs in the world, due to the aging of the population and the increase in demography.

Finally, certain segments such as biomedicines are currently experiencing significant growth and offer opportunities that Pfizer could seize.

Who Are the Investors in Pfizer Shares – Shareholding

The Business Model

The Pfizer group divides its products into three large main poles with:

• Biopharmaceutical Division (76,2%) – with drugs for the treatment of cancer, inflammatory, autoimmune, infectious, metabolic, cardiovascular and rare diseases, vaccines, etc. The group also manufactures active pharmaceutical ingredients.
• The generic drugs division (19,8%; Upjohn) – With products for the treatment of cardiovascular diseases, nervous system disorders, infectious and respiratory diseases, urology, ophthalmology, etc.
• The OTC products division (4,1%).

Why Invest in Pfizer Stock?

• CA, Income from Pfizer Stock US7170811035
• Clients
• Competitors
• Pfizer Partners?
• History & Background of the Pfizer Company

CA, Income from Pfizer Stock US7170811035

Pfizer's financial statement gives us the following results, a turnover of 81 million dollars with a positive net result of 866 million euros. The company's turnover breaks down as follows:

• Biopharmaceutical products account for 76,2% of sales – Treatment of inflammatory and infectious diseases and others.
• Generic drugs account for 19,8% of sales – Treatment of cardiovascular and respiratory diseases, respiratory, urological, ophthalmological, nervous system and other dysfunctions.
• OTC products for 4,1% of turnover.

Clients

Pfizer's main customers are people who need medication to complete their treatment. Pfizer concentrates a large part of its investments in biopharmaceuticals. It develops medicines and vaccines intended for everyone's health.

Competitors

In the field of pharmaceuticals, the current competitors of Pfizer are the following:

• Roche
• Novartis
• novavax
• Bayer
• Merck
• Bristol myers
• Medtronic
• Johnson & Johnson
• Cox
• Sanofi
• Genfit 
• IPSEN
• Onxeo
• Nicox
• AB Science
• Modern
• argenx

Pfizer Partners?

• LianBio
• Post to
• Abbvie
• Biogen
• Arvinas

History & Journey of the Pfizer Company

• 1949 – Creation of the company.
• 1861 – Pfizer supplies the army during the Civil War.
• 1868 – Purchase of a commercial building in Manhattan
• 1900 – Expansion of the company: establishment of subsidiaries throughout America and the independent branch in Chicago.
• 1923 – First fermentation plant: industrial citric acid fermentation plant.
• 1951 – International expansion: establishment of Pfizer subsidiaries in Belgium, Brazil, Canada, Cuba, England, Mexico, Panama and Puerto Rico.
• 1959 – Pfizer AG is founded in Switzerland.
• 1971 – New production site: acquisition of Heinrich Mack Nachf. GmbH & Co. KG, Illertissen.
• 2000 – Business expansion: Warner-Lambert and Parke-Davis join the Pfizer group.
• 2003 – Takeover of Pharmacia (which merged with Upjohn in 1966).
• 2005 – Acquisition of Vicuron Pharmaceuticals: Pfizer acquires the American pharmaceutical company Vicuron Pharmaceuticals.
• 2007 – Alliance with the University of Zurich: strategic alliance with the University of Zurich in the field of cardiovascular research. The commitment over 5 years amounts to 6 million US dollars. Bristol-Myers Squibb and Pfizer begin global collaboration.
• 2009 – Extension of the portfolio: signing of license agreements with Aurobindo and Claris, Pfizer thus expands the portfolio of drugs established in the United States and Europe. Acquisition of Wyeth, creation of two separate research organizations: PharmaTherapeutics and BioTherapeutics.
• 2010 – Takeover of King Pharmaceuticals.
• 2011 – Sale of Capsugel: Pfizer sells Capsugel to a subsidiary of KRR. Partnership with Humana.
• 2012 – Sale of the Nutrition BU (Nutrition Business Unit).
• 2014 – Vaccine acquisition: Acquisition of approved vaccines under license from Baxter.
• 2015 – Sterile injectables: with the acquisition of Hospira, the Pfizer group becomes the world leader in the field of sterile injectables.
• 2016 – Further business expansion: acquisition of Anacor Pharmaceuticals (inflammatory and immune diseases), Bamboo Therapeutics (gene therapy), as well as approved anti-infectives from AstraZeneca and Medivation (oncology).
• 2019 – Acquisition of Therachon (Rare Disease) and Array BioPharma (clinical-stage oncology products).
• 2020 – Announcement from the Pfizer group and BioNTech: the two announce that they have found a vaccine against Covid 19 which is 95% effective, Tozinameran.
• 2025 – Acquisition of Trillium and Arena Pharmaceuticals.

Stock Investing on Pfizer – Most Promising Stock Investing?

In conclusion, given the results of the analysis we have made in this article and the opinions of analysts, investing in Pfizer Group shares on the stock market is very interesting.

Having recently had success with its vaccine against Covid 19, Pfizer has what it takes to remain at the top of the pharmaceutical industry in the world. We therefore advise adding Pfizer stock to your portfolio for this year 2026 and you should do it now, because the price is still very competitive.